Shriya is one in a million. For starters, shes a 9-year-old girl who will talk with anyone. Shes always upbeat and friendly, calling hello to everyone who walks by, even strangers.
Shes so brave, and shes such a chatterbox, says her father, Shyam.
Those are rare traits in a child, but what makes Shriya truly rare is having been born with Schimke immuno-osseous dysplasia (SIOD)a disease that affects just one in every million children in North America. Its fitting that Shriya was the recipient of Stanford Childrens Healths 1,000th stem cell transplantbeing the rare child that she is.
Shriya represents a new frontier of the stem cell transplantation field, so its incredibly exciting that she was our 1,000th stem cell patient, says Alice Bertaina, MD, PhD, section chief of the Pediatric Division of Stem Cell Transplantation and Regenerative Medicine and co-director of the Bass Center for Childhood Cancer and Blood Diseases at Lucile Packard Childrens Hospital Stanford.
SIOD affects multiple systems in the body, including the kidneys, heart, arteries, thyroid, lungs, nerves, and immune system. Children with SIOD are also short-statured. SIOD occurs when both the mother and father carry an abnormal gene.
When we first heard Shriya had SIOD, we couldnt believe it. At age 4, the only concern we had was her short height. We expected it to be fixed with growth hormones. Instead, we heard she had a rare, incurable disease, Shyam says.
Children with SIOD struggle with immune system problems and kidney disease that leads to kidney failure. All of this leaves a child fatigued and ill, including Shriya, who started experiencing kidney disease at the age of 5.
She could only run a few steps before getting tired, and she had to spend 14 hours a day on dialysis, Shyam says.
Shriyas parents were offered a stem cell transplant (also called a bone marrow transplant) in 2016 at another hospital, but at that time the odds of success, a mere 20%, were not worth the risk. By 2019, doctors at Stanford Childrens Health were investigating a much better option: a potential cure for their daughters rare disease.
Before we came to Stanford, all we could do was dream about a real treatment for Shriya. Stanford offered something that we never imagined would be possible, and its totally a dream come true, Shyam says.
Stanford Childrens Healths treatment for SIOD is a two-transplant approach that potentially eliminates the risk of rejection that comes with kidney transplantsand the anti-rejection drugs that accompany them. The game changer is the use of haploidentical stem cell transplant, which provides a child with a new immune system, followed by a kidney transplant from the same donor, usually a parent. Having one donor for both transplants dramatically lowers the risk of kidney rejection and the need for long-term immunosuppression.
With haploidentical stem cell transplants, we expand options for children who dont have a fully matched donor by using a partially matched donor, Dr. Bertaina says.
To make graft-versus-host disease (GvHD) even less likely, Dr. Bertainathe worldwide pioneer and foremost expert in alpha/beta T-cell depleted haploidentical stem cell transplantationselectively eliminates the immune systems cells (alpha/beta T cells) from the donor stem cells. She has been using this technique regularly to treat children with cancers and blood diseases, so applying it to SIOD patients was a new venture. Stanford Childrens Health has treated three SIOD patients with this method so farShriya and the Davenport siblings.
With the first SIOD patient it was almost an unthinkable idea, and now its a reality. We can offer children this chance at a cure, and thats very exciting, Dr. Bertaina adds.
Shriya received her stem cell transplant in January 2020 and her kidney transplant in the middle of the COVID-19 pandemic in July 2020. Both transplants went well.
The nice part of doing a bone marrow transplant first is that it makes the body think the kidney is her own, so the kidney could last a lifetime, says Amy Gallo, MD, surgical director of the pediatric kidney transplant program.
Traditionally, kidney transplants last only about 10 to 12 years because of the constant threat of rejection. Anti-rejection medicines help, but they come with the cost of side effects. By lessening the risk of rejection with this new, two-transplant approach, the hope is that children like Shriya can live beyond childhood and become adults, free from medicines and with functioning kidneys.
There have been multiple reports of kids with SIOD getting kidney transplants and dying because they could not tolerate the anti-rejection medicines. Thats why we decided to try something radically groundbreaking, says Paul Grimm, MD, medical director of the pediatric nephrology program.
Shriya went from taking 10 medicines right after her kidney transplant to taking none, today, Shyam says. Before the transplants, she had energy to climb only one set of stairs. Now, she runs up and down them all day long.
This unique, revolutionary approach to treating SIOD could be used to treat other incurable diseases, like cystinosis (a genetic disorder that affects multiple organs) and focal segmental glomerulosclerosis (FSGS), a type of kidney disease. Doctors at Stanford Childrens Health are exploring the possibilities.
SIOD is the first attempt at this two-transplant approach. We are very optimistic that it could be used for other rare, genetic diseases, but its so cutting-edge that we are moving ahead cautiously, Dr. Grimm says. Wouldnt it be wonderful if one day we could offer it to children with all types of kidney disease?
Shriyas body had difficulty detoxifying drugs, so her doctors were careful to give her just enough to condition her bone marrow to make room for the stem cell transplant. Dr. Grimm describes Dr. Bertaina as a chef tasting a stew to decide the perfect recipe for success.
We cannot say enough good things about Stanford. The doctors are like angels sent from heaven, says Shriyas mom, Rithula. We dont have family nearby, but the doctors and nurses were like a second family to us.
Historically, children with SIOD live to a mean age of 9. Shriya is breaking those odds and living a symptom-free life, today.
We have definitely improved her current quality of her life. Her energy is amazing, the way she runs around, Dr. Grimm says. We are hopeful that the stem cell transplant might cure the underlying disease.
There are a million things that Shriya wants to do. Thanks to this unique treatment approach for SIOD, she now has the energy to try them. First on her list was learning how to ride a scooter. Now, shes mastering riding a bike. After that, who knows? The possibilities are endlessjust like Shriyas love for life.
Learn more at kidneytransplant.stanfordchildrens.org >
Read the rest here:
- FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz IND for Stroke Treatment - KPVI News 6 - May 14th, 2021
- Duluth health center specializes in regenerative medicine, hormone replacement therapy - Duluth News Tribune - May 14th, 2021
- Dr. Krger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma - OncLive - May 14th, 2021
- Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its... - May 14th, 2021
- Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon Delivered Tumor-Focused Interferon ExpressionData presented at the 2021 American Society... - May 14th, 2021
- ViaCyte To Participate In World Medical Innovation Forum Panel On Future Of Cell Therapy For Type 1 Diabetes - PRNewswire - May 14th, 2021
- Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress - Business Wire - May 14th, 2021
- Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May - Business Wire - May 14th, 2021
- Outlook for multiple myeloma: Figures and factors that affect it - Medical News Today - May 14th, 2021
- Global Regenerative Medicine for Cartilage Market Report 2021: Companies are Continuously Focusing on Introducing New Technologies to Survive in the... - May 14th, 2021
- UB celebrates 175th anniversary of its origins in study of medicine - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - May 14th, 2021
- Stem cell therapy for COVID-19 and ARDS - News-Medical.Net - May 7th, 2021
- Experimental COVID-19 lung treatment being tested at Ontario hospitals - CityNews Toronto - May 7th, 2021
- EP. 4: Optimizing Patient Selection for CAR T-Cell Therapy - OncLive - May 7th, 2021
- Could stem cells improve the outcome of ARDS in severe COVID-19? - News-Medical.Net - May 7th, 2021
- Motixafortide Reaches Primary End Point of Improved Stem Cell Mobilization in Multiple Myeloma Trial - Cancer Network - May 7th, 2021
- Restricting the Growth and Spread of Head and Neck Cancers - Technology Networks - May 7th, 2021
- The global stem cell therapy market is projected to reach USD 401 million by 2026 from - GlobeNewswire - May 7th, 2021
- UCLA team discovers how to restrict growth, spread of head and neck cancers | UCLA - UCLA Newsroom - May 7th, 2021
- NUS scientists found a key element that affects how genes are expressed in blood stem cells - Newswise - May 7th, 2021
- Citius Pharmaceuticals to Present Mino-Lok and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13... - May 7th, 2021
- Mesoblast says its stem cell treatment saved lives of severely ill COVID patients - Stockhead - May 2nd, 2021
- Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants - News-Medical.Net - May 2nd, 2021
- Antiviral T cells protected, viable as off-the-shelf treatment for painful complication stem cells - Microbioz India - May 2nd, 2021
- Desperate family of boy, 9, with leukaemia have 10 days to save his life... - The Sun - May 2nd, 2021
- Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy - GlobeNewswire - May 2nd, 2021
- Investigating CAR T-Cell Therapy for Use in Different Disease Types - Targeted Oncology - May 2nd, 2021
- Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in... - May 2nd, 2021
- Thomas Smeenk on Hemostemix's autologous stem cell therapy technology and why some call it 'the fountain of youth' - InvestorIntel - April 28th, 2021
- Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer... - April 28th, 2021
- Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting - GlobeNewswire - April 28th, 2021
- Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low... - April 28th, 2021
- A review of baculovirus vectors in gene therapy | BTT - Dove Medical Press - April 28th, 2021
- Stem Cell Therapy for COPD: Hope and Exploitation - DocWire News - April 26th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - Business Wire - April 26th, 2021
- Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and... - April 24th, 2021
- Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment - DocWire... - April 24th, 2021
- Advancing the Development of Safe and Effective Regenerative Medicine Products | FDA - FDA.gov - April 24th, 2021
- New method helps map the specialized diversity and spatial location of cells within a tissue or tumor - News-Medical.Net - April 24th, 2021
- Chimeric embryo may have medical implications The Campus - The Campus - April 24th, 2021
- Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National... - April 24th, 2021
- Guenther Koehne, MD, Highlights Recent Advancements in the Treatment of Blood Cancers - Oncology Learning Network - April 24th, 2021
- Rinri Therapeutics raises 10 million to advance stem cell therapy for hearing loss - The Star - April 24th, 2021
- Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia - Sickle Cell Anemia News - April 24th, 2021
- Hodgkin lymphoma: Symptoms, outlook, treatment, and more - Medical News Today - April 24th, 2021
- Tissue Repair, Mitochondrial Function and Wound Healing Explored in 2021 APS Presidents Symposium - Newswise - April 24th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - BioSpace - April 20th, 2021
- Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus - Proactive Investors USA - April 20th, 2021
- Rinri Therapeutics Raises 10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss -... - April 20th, 2021
- Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple... - April 20th, 2021
- FDA Grants Orphan Drug Status to Novel IRAK4 Inhibitor in AML and MDS - Targeted Oncology - April 20th, 2021
- Vertex Drops $900 Million to Expand Partnership with CRISPR Therapeutics - BioSpace - April 20th, 2021
- Kaleido Biosciences Announces Collaboration with Robert Jenq, MD, to Explore Potential of its Microbiome Metabolic Therapies (MMT) in Preventing... - April 20th, 2021
- Partner Content | Being bionic: the future of regenerative medicine - TheSpec.com - April 14th, 2021
- Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant Services - Wexner Medical Center - The Ohio State... - April 14th, 2021
- Leukemia Cutis: Symptoms and Treatment - Healthline - April 14th, 2021
- Green: Variants and outbreaks continue to put stress on hospitals - Vermont Biz - April 14th, 2021
- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends - GlobeNewswire - April 14th, 2021
- Consortium to investigate role of neurofilament light chain in neurodegenerative diseases Washington University School of Medicine in St. Louis -... - April 14th, 2021
- Man's heart healed by stem cell therapy and love of an old flame - Leeds Live - April 12th, 2021
- New pediatric cancer treatment method being used in Iran - Tehran Times - April 12th, 2021
- Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types - Technology Networks - April 12th, 2021
- Home : Stem Cell Treatments - April 10th, 2021
- Researchers discover unique regenerative property of cells in the early human embryo - News-Medical.net - April 10th, 2021
- Study reveals sex-differences in aging of the brain stem cell niche - News-Medical.net - April 10th, 2021
- Antibiotics need further study in cancer treatments - Chicago Daily Herald - April 10th, 2021
- Prolonged infection and inflammation drain immune responses as we age - Baylor College of Medicine News - April 10th, 2021
- Toward a transformative therapy for sickle cell patients - News-Medical.Net - April 10th, 2021
- Mass. Residents 55+ Or With 1 Medical Condition Can Now Get COVID Vaccine | WBZ NewsRadio 1030 - iHeartRadio - April 6th, 2021
- Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - DocWire News - April 6th, 2021
- BioRestorative Therapies Announces Appointment of Nickolay V. Kukekov, Ph.D to its Board of Directors - BioSpace - April 6th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 3rd, 2021
- Novel T-Cell Therapy MT-401 Under Evaluation in Post-Transplant AML - OncLive - April 3rd, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 3rd, 2021
- Do Therapies for Alzheimer's & Parkinson's that Clear Abnormal Brain Proteins Make the Diseases Worse? - BioSpace - April 3rd, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 1st, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 1st, 2021
- The Government's Watchful Eye on Fraud Stemming from Stem Cell Therapy - Lexology - April 1st, 2021
- Introducing a neuro regenerative gene into mice with spinal cord injury improves motor function - News-Medical.net - April 1st, 2021
- Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy... - April 1st, 2021